Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
| ▸ | PRKCB | P05771 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCH | P24723 | 1/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63754 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL272506 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| Hydrogen Peroxide SCHEMBL15769657 | 0.98 | SMN1; SMN2 (0.97) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| Methylamine SCHEMBL9699690 | 0.97 | SMN1; SMN2 (0.94) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL10586725 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL28965396 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL23199737 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL19821621 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL4989896 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAAKT1ESR1ADORA3 | |
| SCHEMBL1853865 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2LMNAAKT1ESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254428-A2 | BIOACTIVE TELODENDRIMER NANODRUG FOR IMMUNE MODULATION AND DRUG DELIVERY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024192034-A2 | BYSTANDER ANTIGEN ENHANCEMENT OF TUMOR CELL LYSATE IMMUNOGENICITY | CORNER THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | claimed |
| EP-3584574-B1 | DIAGNOSTIC METHODS, THERAPEUTIC AGENTS AND USES THEREOF | METABOLON INC (US) | 2024-06-12 | — | — | EP | claimed |
| CN-117618299-A | Pleurotus rhodochrous mycelium metabolite, preparation method and application thereof | 福建百想生物科技有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-114814022-B | Application of ganoderma lucidum glycol and glycerol-3-phosphorylcholine as biomarkers in detecting effectiveness of heat treatment of papaya | 中国检验检疫科学研究院 | 2023-10-13 | — | — | CN | claimed |
| US-20230217977-A1 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH | 2023-07-13 | — | — | US | claimed |
| CN-116211828-A | Liposome nano platform with inflammation recognition capability and preparation method and application thereof | 南昌大学 | 2023-06-06 | — | — | CN | claimed |
| CN-110907541-B | Method for simultaneously measuring R-epoxypropanol and R-3-chlorine-1,2-propylene glycol residues in L-alpha-glycerophosphorylcholine | 上高县协和生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115667509-A | Compositions and methods for RNA synthesis | 螺旋纳米技术公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4110328-A1 | INTERVENTION STRATEGY FOR PREVENTION OR TREATMENT OF DIABETES MELLITUS, AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE OR CARDIOVASCULAR DISEASE | Academisch Medisch Centrum (NL) | 2023-01-04 | — | — | EP | claimed |
| EP-1799263-A4 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | HARVARD COLLEGE (US) | 2009-07-29 | — | — | EP | claimed |
| EP-1973986-A2 | BIOACTIVE COMPLEX COMPOSITIONS AND METHODS OF USE THEREOF | The Texas A & M University System (US) | 2008-10-01 | — | — | EP | claimed |
| EP-1954254-A2 | MODULATING ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS | The President and Fellows of Harvard College (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007079443-A2 | BIOACTIVE COMPLEX COMPOSITIONS AND METHODS OF USE THEREOF | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1799263-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | The President and Fellows of Harvard College (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2007053747-A2 | MODULATING ENDOPLASMIC RETICULUM STRESS IN THE TREATMENT OF TUBEROUS SCLEROSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-10 | — | — | WO | claimed |
| US-20070085059-A1 | Bioactive Complexes Compositions and Methods of Use Thereof | TEXAS A&M UNIVERSITY SYSTEM (US) | 2007-04-19 | — | — | US | claimed |
| US-20060073213-A1 | Reducing ER stress in the treatment of obesity and diabetes | POPE, BILL J. | 2006-04-06 | — | — | US | claimed |
| WO-2006031931-A2 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-03-23 | — | — | WO | claimed |
| EP-0354474-A2 | Method and composition for cryopreservation of tissue | Glonek, Thomas (US) | 1990-02-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060073213-A1 | Reducing ER stress in the treatment of obesity and diabetes | HSPA5, GPR119, GIPR | SMN1; SMN2 3289/4885LMNA 2110/4885AKT1 3833/4885 |
| US-20230217977-A1 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | CHAT, CHKA, CHKB | SMN1; SMN2 2084/4885LMNA 4062/4885AKT1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.